June 25, 2014 — Thanks to its excellent dielectric properties and a reliable surface finish, a high-quality alumina ceramic from Morgan Advanced Materials is now being successfully used in radiotherapy equipment for oncology treatment.

Deranox 970 is a high-density, non-porous and vacuum-tight material with a 97 percent aluminium oxide content, which provides excellent electrical insulation. It is frequently used in high-vacuum systems, in laser and microscope applications and as an insulator in medical and scientific equipment, and has now been specified as the sealing element for RF windows in radiotherapy equipment.

Acting as a mechanical seal at either end of the vacuum chamber through which electron beams pass in the radiotherapy process, RF windows maintain the integrity of the vacuum, allowing electrons to pass through while preventing both ingress of contaminants and vacuum leakage.

Yannick Galais from Morgan explained: “While most solutions for RF windows contain around 97 percent alumina, it is the remaining 3 percent that makes all the difference in dielectric performance. The alumina ceramic formulation of Deranox 970 provides a high dielectric constant — 9.85 and 9.84 at 2.8GHz and 2.9GHz respectively — and low loss tangent — 0.00109 and 0.00110 at 2.8GHz and 2.9GHz respectively. Externally tested and verified by an independent and fully accredited testing house to an internationally recognized standard, ASTM D2520, these properties contribute to excellent stability at high frequencies.

“Our sophisticated powder manufacturing processes provide excellent repeatability from batch to batch, between batches, which is a key parameter in tuning the nominal wavelength and beam frequency, which will ultimately determine the performance of the of the radiotherapy machine. Our precision machining capabilities guarantee a consistent surface finish and flatness preventing RF reflectance and thus eliminating heat and leakage over time. Providing an impurity-free surface finish also improves the performance of the radiotherapy machinery by removing any potential for oxidation on the RF window,” Galais said.

Using advanced simulation techniques and extensive modeling, Deranox 970 has been comprehensively tested for radiotherapy applications prior to the prototype stage to ensure its suitability — followed by in-depth real-life testing to ensure optimum performance within a very tight tolerance range. Developed alongside Deranox 970 for radiotherapy equipment, Morgan has also introduced a tailored moly-manganese metalizing ink to facilitate the bonding process when the RF window is brazed to the body of the machine, creating the optimum seal and safeguarding the vacuum. As each RF window is individually designed for specific machinery, Morgan’s inks are custom formulated for each material grade. In addition to the ceramic, Morgan is able to supply the complete RF window sub-assembly including mounting flanges. Innovative design features allow Morgan to offer ceramic RF windows brazed inside the oxygen free copper (OFC) vacuum chamber.

Galais continued, “RF windows made of Deranox 970 will last the lifetime of the radiotherapy equipment — generally 20 years plus. Within the highly time-sensitive oncology treatment pathway, disruption to therapy machinery is simply not an option and failure of an RF window will often require full replacement of the radiotherapy machine, at enormous cost to the hospital trust and causing unacceptable delays for patients. The purity of our Deranox 970 material, coupled with its reliable dielectric properties and Morgan’s extensive modeling and test processes, ensure a high-quality RF window solution with long-lasting performance.”

For more information: www.morganadvancedmaterials.com


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
Subscribe Now